Objectives: To examine susceptibilities of Bacillus anthracis and related species to 24 antimicrobials using and concurrently comparing two methods. cereus, three were resistant to clindamycin and one was resistant to clarithromycin and clindamycin. One B. mycoides was intermediately resistant to quinupristin/dalfopristin and meropenem and one was clindamycin-resistant. All B. pseudomycoides were clindamycin-resistant with one quinupristin/ dalfopristin-resistant. Two B. mycoides/pseudomycoides were intermediately resistant to quinupristin/ dalfopristin and clindamycin and a third was intermediately resistant to clindamycin alone. All isolates were susceptible to chloramphenicol, ciprofloxacin, gatifloxacin, gentamicin, levofloxacin, linezolid, moxifloxacin, rifampicin, streptomycin, tetracycline, tigecycline and vancomycin.
Introduction
In the United States, human cases of anthrax are rare with the most recent cases occurring in 2001 and 2006. 1 -3 European cases involved travellers who had contact with mammal carcasses. 4 -6 Bacillus cereus causes gastrointestinal distress, necrotic enteritis, liver failure, bacteraemia, endocarditis, meningitis, pneumonia and skin lesions. 7 -15 Long considered nonpathogenic and used extensively for insect pest control, Bacillus thuringiensis has been implicated in burn wound infections and food-poisoning. 16, 17 Of the other B. cereus group members, Bacillus mycoides, Bacillus pseudomycoides and Bacillus weihenstephanensis, only B. mycoides has been implicated in human infection (endophthalmitis). 18 Although Bacillus anthracis has been reported as susceptible to a limited number of antimicrobials, resistance to penicillin, erythromycin and quinolones has been noted. 19 -25 Therefore, it is conceivable that an isolate could be engineered to be resistant to one or more antimicrobials. 26 -28 Because susceptibility testing of B. anthracis in the sentinel and reference laboratories is not recommended by the Centers for Disease Control and Prevention (CDC) who prefers to perform the testing at the national laboratory, the attending physician will treat a patient with a suspected B. anthracis infection empirically until a report is received from the CDC. 29 In contrast, B. cereus, typically resistant only to b-lactams, can be tested in the clinical laboratory. 30, 31 Reports of resistance in B. cereus to erythromycin and tetracyclines in the United States and Europe predict the development of further resistance. 32 -34 B. thuringiensis and B. mycoides can be difficult to distinguish from B. cereus before susceptibility tests are performed. B. pseudomycoides cannot be distinguished from B. mycoides without fatty acid methyl-ester analysis and its antibiogram is unknown. 35 Thus, all four species were included in the study.
Mohammed et al. 36 at the CDC reported that the Etest w by AB BIODISK (North America Inc., Piscataway, NJ, USA) could be used with B. anthracis and this implies that the method can be used for testing B. cereus. Turnbull et al. 25 also compared the Etest w to agar dilution tests for nine antimicrobials and extended this testing to include B. cereus, B. thuringiensis and B. mycoides. The dual purpose of this research was to (i) expand our knowledge of susceptibility patterns of B. anthracis and related Bacillus against a larger number of antimicrobials using the Etest w and (ii) to compare the Etest w method with the Sensititre w automated microbroth dilution method with selected antimicrobials.
Materials and methods

Bacteria and growth conditions
We examined 95 Bacillus isolates: 18 B. anthracis, 42 B. cereus, 5 B. mycoides, 5 B. mycoides/pseudomycoides, 6 B. pseudomycoides and 19 B. thuringiensis. The B. anthracis isolates were received from the Florida Department of Health, Bureau of Laboratories, Tampa, FL, USA (FDOH), the NIH Biodefense and Emerging Infections Research Resources Repository (BEI Resources, Bethesda, MD, USA) or isolated from diverse environment and soil samples. The other Bacillus isolates in the study were received from FDOH, American Type Culture Collection (ATCC, Manassas, VA, USA) or Agriculture Research Service Culture Collection (ARSCC, Peoria, IL, USA), purchased as commercial pesticide products or isolated from various non-replicate environmental, marine and soil samples (one isolate per sample). Only one B. anthracis isolate was known to be from a human culture. Six of the B. thuringiensis isolates were potentially related. 37 While all manipulations of B. anthracis isolates were performed in a class 2 biological safety cabinet, B. anthracis Pasteur isolates were stored and handled in a biosafety level 2 laboratory using biosafety level 3 (BSL3) practices and all other B. anthracis isolates were handled in a BSL3 laboratory. This arrangement followed the Institutional Bio-safety Committee requirements at USF. All safety protocols and requirements required by US federal regulation DHHS 42 CFR 73 were strictly met. Prior to susceptibility tests, the bacteria were grown on tryptic soy agar supplemented with 5% sheep red blood cells [blood agar (BA)] (Remel, Lenexa, KS, USA). All plates were incubated at 30 or 358C (+2) overnight (18 h) in ambient air before testing.
Susceptibility tests
All Etest
w susceptibility tests were set up on Mueller -Hinton agar plates (Remel) and read following the manufacturer's directions. Plates were incubated at 30 or 358C for 18, 24 and 48 h. Interpretation of the MIC values followed CLSI standards.
-40
Staphylococcus aureus ATCC 29213 was included as a control.
The Sensititre w by TREK Diagnostic Systems (Cleveland, OH, USA) is an automatic system that uses a 96-well plate format with a panel of several antimicrobials that are precision dosed at appropriate dilutions and equates to the classical microbroth dilution method. The instrument detects growth as a fluorescent substrate is utilized by bacterial surface enzymes. In addition, isolates were grown on tryptic soy agar (Fisher Scientific, Suwanee, GA, USA) supplemented with 0.06 mg/L erythromycin (Sigma-Aldrich, St Louis, MO, USA) and retested against clindamycin. Tests for the b-lactams oxacillin and meropenem were repeated and read at 18, 24 and 48 h.
Results
The susceptibility tests with Etest w and the Sensititre w microbroth dilution methods, using either 30 or 358C incubation temperatures, gave identical or near identical MICs (less than a 2-fold dilution difference) for all of the antimicrobials (except for trimethoprim/sulfamethoxazole) at 18, 24 and 48 h readings. This resulted in identical or near identical MIC 50 s and MIC 90 s for each antimicrobial. In general, with both methods, the endpoints for the 23 antimicrobials were easier to read at 24 h than 18 h, but we did not see any increase in MICs at the later time point. Even extending the time frame to 48 h did not produce higher MICs. The few times more growth was noted at 48 h with the Etest w , the new MIC values were less than or equal to a 2-fold difference with either temperature (data not shown) and were not considered a true increase in MIC. This agrees with other researchers. 25 Because of the reports of trimethoprim/sulfamethoxazole resistance 41, 42 (Table 1 ). This was due to the MIC values overlapping the susceptible breakpoint of 0.5 mg/L and was not considered a method discrepancy.
The majority of the B. cereus and all of the B. thuringiensis isolates were resistant to amoxicillin, ampicillin, ceftriaxone, penicillin and oxacillin while susceptible to the remaining antimicrobials ( Figure 1 ). Resistance in B. cereus was uncommon as six (14%) isolates were resistant to meropenem, seven (17%) were intermediate or resistant (inducible and constitutive) to clindamycin and only a single (2%) isolate was resistant to both clarithromycin and erythromycin (Tables 1 and 2 ). Only one isolate of the seven that were intermediately resistant to erythromycin by Etest w (1 mg/L) was called susceptible by Sensititre w (0.5 mg/L). A single B. thuringiensis had intermediate resistance to clindamycin. The six potentially related B. thuringiensis isolates did not demonstrate identical MIC values for all of the antimicrobials, but since antibiograms can differ within a related population of strains, this did not rule out their possible relatedness.
One B. mycoides, five B. pseudomycoides and two B. mycoides/pseudomycoides isolates were susceptible to the b-lactams, whereas the other isolates of these species were resistant ( Table 1 ). The tests were repeated and tests held for an additional 24 h but the MICs remained the same. Sporadic intermediate resistance was seen against meropenem, quinupristin/ dalfopristin and clindamycin. All of the B. pseudomycoides were intermediate or resistant to clindamycin, whereas the B. mycoides and B. mycoides/pseudomycoides were generally susceptible.
Discussion
When 16 antimicrobials were tested by both Sensititre w and Etest w , the two techniques produced for 15 of the antimicrobials identical or near identical (less than a 2-fold dilution) results at either 30 or 358C when read after 24 h of incubation. Attempts at discerning growth at ,24 h of incubation rendered unreliable results no matter the method or the antimicrobial tested. This difficulty appeared to be due to the growth traits of the bacteria and not to the particular test method especially for B. mycoides and B. pseudomycoides isolates since they commonly produced their characteristic rhizoid-like branching. Although we were not able to fully compare the two methods with the other eight antimicrobials, we expect that both the Etest w and the microbroth dilution format by Sensititre w will be valid to use. Like the Etest w , the Sensititre w protocols can be executed within a Bio-Safety Cabinet (BSC). The Sensititre w instrument has a modular design in which the inoculating unit is small The breakpoints (in mg/L) used for ciprofloxacin, penicillin and tetracycline were for B. anthracis while the breakpoints used for the other antimicrobials were for Staphylococcus spp. as recommended by the CDC and the CLSI guidelines M100-S16 (2006) The values given for S. aureus ATCC 29213 are the means and ranges of 12 repeat tests. j CLSI approved standard M100-S16 38 states that no strains resistant to the tested drug were available for establishing standards. Only susceptible breakpoints established for these drugs.
k Trimethoprim/sulfamethoxazole was tested against B. anthracis because the antimicrobial is already on the Gram-positive panel offered by the manufacturer and unexpected susceptibility results were noted. 33, 40 The fact that only 17% of the B. anthracis demonstrated any resistance to erythromycin, which is much lower than that found previously in one study, 25 may reflect the smaller number of B. anthracis examined in this work. The lack of resistance to tetracycline by any of the isolates was surprising since many came from environmental samples obtained from rural areas where farm animals may be routinely treated with tetracyclines. 33, 34 This paper demonstrates that most of the Bacillus isolates (no matter the species) were resistant to trimethoprim/sulfamethoxazole if the test was performed at 308C and not at the CLSI recommended 358C. Therefore, we suggest that this therapeutic combination not be tested nor reported for any isolates of the B. cereus group, especially if dealing with a B. cereus or B. thuringiensis causing a life-threatening infection or a suspected B. anthracis. It was interesting to note that all of the B. anthracis isolates were resistant to trimethoprim/sulfamethoxazole when tested in a broth at either 30 or 358C, whereas most of the other Bacillus species did not reveal their resistance to the antimicrobial until after 48 h of incubation at 308C. The lag in demonstrating resistance may be due to a low number of resistant individual organisms in a largely susceptible population that takes time to be observable in a well of broth or on an agar plate. Alternatively, there may be a more molecular-based reason for this difference. The actual mechanism for this false susceptibility is unknown, but one reason may be that the two enzyme targets of trimethoprim/sulfamethoxazole have different shapes at the higher temperature. This change in shape could allow the antimicrobials access to the enzymes and thus inhibit or slow their usual activity. The temperature/resistance differences could be useful in distinguishing B. anthracis from its relatives. This is the first report of B. mycoides and B. pseudomycoides being susceptible to the b-lactams. The significance of this becomes important when their phenotypic characteristics are reviewed. Although some of the isolates produced enough haemolysin to give a b-haemolytic pattern, others did not. The latter were weakly haemolytic under the colony, mimicking a haemolysis pattern that has been seen in B. anthracis. 30 These latter isolates were non-motile and did not readily display the characteristic spreading of these two species. Therefore, a sentinel laboratory would consider these cultures suspicious for B. anthracis and send them to a reference laboratory. If susceptibility tests were done before realizing that the organism was a potential B. anthracis, the penicillin susceptibility would give weight to the suspicion that they were indeed B. anthracis. In the meantime, the clinician would start prophylactic therapy. Our laboratory is currently exploring different characteristics of these isolates that might help to easily separate them from B. anthracis in the early stages of identification.
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Under current guidelines in the United States, ciprofloxacin is the drug of choice for prophylaxis. For therapy, the CDC recommends a combination therapy of ciprofloxacin and at least one other efficacious antibiotic, while the CDC performs the MICs on a limited battery of antimicrobials: ciprofloxacin, clindamycin, erythromycin, penicillin, rifampicin, tetracycline and vancomycin. 3, 44 And although B. anthracis can produce penicillinase and cephalosporinase, penicillin historically has been useful for treatment, especially when combined with streptomycin. 45 Because ciprofloxacin is the drug of choice for both prophylaxis and treatment, it is possible that in the event of a biothreat or accidental exposure to B. anthracis, the ciprofloxacin supply could be seriously depleted. To help ease the burden, the newer quinolones could be used in the place of ciprofloxacin with successful expectations since B. anthracis isolates were fully susceptible to all of the quinolones. The newer antimicrobials such as linezolid, daptomycin and tigecycline also offer newer choices for therapy against any of the Bacillus species (Table 2) .
For the treatment of B. cereus, B. thuringiensis and other Bacillus infections, there is little advice found for treatment. B. cereus is usually susceptible to aminoglycosides, chloramphenicol, clindamycin, erythromycin, tetracycline and vancomycin. 30 Yet various Bacillus species in this study demonstrated small populations with some form of resistance to clindamycin and erythromycin. Therefore the wider choice of newer antimicrobials can be useful in treating an infection.
In conclusion, this paper has broadened the number of antimicrobials potentially useful against B. anthracis, B. cereus, B. mycoides, B. pseudomycoides and B. thuringiensis. In vitro testing by Etest w and Sensititre w methods produced comparable results. Resistance in these species to trimethoprim/sulfamethoxazole was confirmed by using a lower testing temperature and longer incubation time during testing.
